Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

FGD5 sustains vascular endothelial growth factor A (VEGFA) signaling through inhibition of proteasome-mediated VEGF receptor 2 degradation.

Heldin J, O'Callaghan P, Hernández Vera R, Fuchs PF, Gerwins P, Kreuger J.

Cell Signal. 2017 Dec;40:125-132. doi: 10.1016/j.cellsig.2017.09.009. Epub 2017 Sep 18.

PMID:
28927665
2.

Endoplasmic reticulum stress enhances fibrosis through IRE1α-mediated degradation of miR-150 and XBP-1 splicing.

Heindryckx F, Binet F, Ponticos M, Rombouts K, Lau J, Kreuger J, Gerwins P.

EMBO Mol Med. 2016 Jul 1;8(7):729-44. doi: 10.15252/emmm.201505925. Print 2016 Jul.

3.

Identification and characterization of VEGF-A-responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans.

Massena S, Christoffersson G, Vågesjö E, Seignez C, Gustafsson K, Binet F, Herrera Hidalgo C, Giraud A, Lomei J, Weström S, Shibuya M, Claesson-Welsh L, Gerwins P, Welsh M, Kreuger J, Phillipson M.

Blood. 2015 Oct 22;126(17):2016-26. doi: 10.1182/blood-2015-03-631572. Epub 2015 Aug 18.

4.

Targeting the tumor stroma in hepatocellular carcinoma.

Heindryckx F, Gerwins P.

World J Hepatol. 2015 Feb 27;7(2):165-76. doi: 10.4254/wjh.v7.i2.165. Review.

5.

The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo.

Strese S, Wickström M, Fuchs PF, Fryknäs M, Gerwins P, Dale T, Larsson R, Gullbo J.

Biochem Pharmacol. 2013 Oct 1;86(7):888-95. doi: 10.1016/j.bcp.2013.07.026. Epub 2013 Aug 8.

PMID:
23933387
6.

MicroRNA-24 suppression of N-deacetylase/N-sulfotransferase-1 (NDST1) reduces endothelial cell responsiveness to vascular endothelial growth factor A (VEGFA).

Kasza Z, Fredlund Fuchs P, Tamm C, Eriksson AS, O'Callaghan P, Heindryckx F, Spillmann D, Larsson E, Le Jan S, Eriksson I, Gerwins P, Kjellén L, Kreuger J.

J Biol Chem. 2013 Sep 6;288(36):25956-63. doi: 10.1074/jbc.M113.484360. Epub 2013 Jul 24.

7.

An in vivo neovascularization assay for screening regulators of angiogenesis and assessing their effects on pre-existing vessels.

Kilarski WW, Petersson L, Fuchs PF, Zielinski MS, Gerwins P.

Angiogenesis. 2012 Dec;15(4):643-55. doi: 10.1007/s10456-012-9287-8. Epub 2012 Aug 24.

8.

Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1.

Larsson E, Fredlund Fuchs P, Heldin J, Barkefors I, Bondjers C, Genové G, Arrondel C, Gerwins P, Kurschat C, Schermer B, Benzing T, Harvey SJ, Kreuger J, Lindahl P.

Genome Med. 2009 Nov 16;1(11):108. doi: 10.1186/gm108.

9.

A new mechanism of blood vessel growth - hope for new treatment strategies.

Kilarski WW, Gerwins P.

Discov Med. 2009 Jun;8(40):23-7.

10.

Biomechanical regulation of blood vessel growth during tissue vascularization.

Kilarski WW, Samolov B, Petersson L, Kvanta A, Gerwins P.

Nat Med. 2009 Jun;15(6):657-64. doi: 10.1038/nm.1985.

PMID:
19483693
11.

Role of aggregated medin in the pathogenesis of thoracic aortic aneurysm and dissection.

Peng S, Larsson A, Wassberg E, Gerwins P, Thelin S, Fu X, Westermark P.

Lab Invest. 2007 Dec;87(12):1195-205. Epub 2007 Oct 1.

12.

Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer.

Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, Westholm JO, Komorowski J, Lassalle P, Cross MJ, Gerwins P.

Exp Cell Res. 2007 Apr 15;313(7):1285-94. Epub 2007 Feb 6.

PMID:
17362927
13.

Lactadherin binds to elastin--a starting point for medin amyloid formation?

Larsson A, Peng S, Persson H, Rosenbloom J, Abrams WR, Wassberg E, Thelin S, Sletten K, Gerwins P, Westermark P.

Amyloid. 2006 Jun;13(2):78-85.

PMID:
16911961
14.

Efficient human interferon-alpha gene transfer to neuroendocrine tumor cells with long-term and stable expression.

Liu M, Kilarski WW, Gerwins P, Oberg K, Zhou Y.

Neuroendocrinology. 2005;82(5-6):264-73. Epub 2006 Apr 24.

PMID:
16721032
15.

An ex vivo model for functional studies of myofibroblasts.

Kilarski WW, Jura N, Gerwins P.

Lab Invest. 2005 May;85(5):643-54.

16.

Src family kinase-inhibitor PP2 reduces focal ischemic brain injury.

Lennmyr F, Ericsson A, Gerwins P, Akterin S, Ahlström H, Terént A.

Acta Neurol Scand. 2004 Sep;110(3):175-9.

PMID:
15285775
17.

Increased brain injury and vascular leakage after pretreatment with p38-inhibitor SB203580 in transient ischemia.

Lennmyr F, Ericsson A, Gerwins P, Ahlström H, Terént A.

Acta Neurol Scand. 2003 Nov;108(5):339-45.

PMID:
14616304
18.

Regulation of endothelial cell differentiation and transformation by H-Ras.

Rennel E, Cross MJ, Klint P, Bai X, Arbiser JL, Gerwins P.

Exp Cell Res. 2003 Nov 15;291(1):189-200.

PMID:
14597419
19.
20.

Activation of mitogen-activated protein kinases in experimental cerebral ischemia.

Lennmyr F, Karlsson S, Gerwins P, Ata KA, Terént A.

Acta Neurol Scand. 2002 Dec;106(6):333-40.

PMID:
12460137
21.

How to make tetracycline-regulated transgene expression go on and off.

Rennel E, Gerwins P.

Anal Biochem. 2002 Oct 1;309(1):79-84.

PMID:
12381365
22.

p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis.

Matsumoto T, Turesson I, Book M, Gerwins P, Claesson-Welsh L.

J Cell Biol. 2002 Jan 7;156(1):149-60. Epub 2002 Jan 7.

23.

Role of the amino-terminal domains of MEKKs in the activation of NF kappa B and MAPK pathways and in the regulation of cell proliferation and apoptosis.

Bonvin C, Guillon A, van Bemmelen MX, Gerwins P, Johnson GL, Widmann C.

Cell Signal. 2002 Feb;14(2):123-31.

PMID:
11781136
24.

Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis.

Gerwins P, Sköldenberg E, Claesson-Welsh L.

Crit Rev Oncol Hematol. 2000 Jun;34(3):185-94. Review.

PMID:
10838264
25.

Differential regulation of CD40-mediated human B cell responses by antibodies directed against different CD40 epitopes.

Sakata N, Hamelmann E, Siadak AW, Terada N, Gerwins P, Aruffo A, Johnson GL, Gelfand EW.

Cell Immunol. 2000 May 1;201(2):109-23.

PMID:
10831320
26.

Differential activation and regulation of mitogen-activated protein kinases through the antigen receptor and CD40 in human B cells.

Sakata N, Kawasome H, Terada N, Gerwins P, Johnson GL, Gelfand EW.

Eur J Immunol. 1999 Sep;29(9):2999-3008. Erratum in: Eur J Immunol 2000 Jun;30(6):1795.

27.

Activation of mitogen-activated protein kinase cascades during priming of human neutrophils by TNF-alpha and GM-CSF.

McLeish KR, Knall C, Ward RA, Gerwins P, Coxon PY, Klein JB, Johnson GL.

J Leukoc Biol. 1998 Oct;64(4):537-45.

PMID:
9766635
28.

Stem cell factor augments Fc epsilon RI-mediated TNF-alpha production and stimulates MAP kinases via a different pathway in MC/9 mast cells.

Ishizuka T, Kawasome H, Terada N, Takeda K, Gerwins P, Keller GM, Johnson GL, Gelfand EW.

J Immunol. 1998 Oct 1;161(7):3624-30.

29.

MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis.

Widmann C, Gerwins P, Johnson NL, Jarpe MB, Johnson GL.

Mol Cell Biol. 1998 Apr;18(4):2416-29.

30.

Mast cell tumor necrosis factor alpha production is regulated by MEK kinases.

Ishizuka T, Terada N, Gerwins P, Hamelmann E, Oshiba A, Fanger GR, Johnson GL, Gelfand EW.

Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6358-63.

31.
33.

Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet activating factor and FMLP.

Nick JA, Avdi NJ, Young SK, Knall C, Gerwins P, Johnson GL, Worthen GS.

J Clin Invest. 1997 Mar 1;99(5):975-86.

34.

MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases?

Fanger GR, Gerwins P, Widmann C, Jarpe MB, Johnson GL.

Curr Opin Genet Dev. 1997 Feb;7(1):67-74. Review.

PMID:
9024636
35.

Activation of a p38 mitogen-activated protein kinase in human neutrophils by lipopolysaccharide.

Nick JA, Avdi NJ, Gerwins P, Johnson GL, Worthen GS.

J Immunol. 1996 Jun 15;156(12):4867-75.

PMID:
8648136
38.

Activation of adenosine A1 and bradykinin receptors increases protein kinase C and phospholipase D activity in smooth muscle cells.

Gerwins P, Fredholm BB.

Naunyn Schmiedebergs Arch Pharmacol. 1995 Feb;351(2):186-93.

PMID:
7770100
39.

A2a/D2 receptor interactions are not observed in COS-7 cells transiently transfected with dopamine D2 and adenosine A2a receptor cDNA.

Snaprud P, Gerwins P, Caron MG, Libert F, Persson H, Fredholm BB, Fuxe K.

Biochem Pharmacol. 1994 Nov 29;48(11):2043-7.

PMID:
7802693
40.
41.
42.

Signalling via G-protein coupled receptors--using adenosine receptors as an example.

Fredholm BB, Gerwins P, Johansson B, Parkinson FE, van der Ploeg I.

Drug Des Discov. 1993;9(3-4):189-97. Review. No abstract available.

PMID:
8400002
45.

Further evidence that propentofylline (HWA 285) influences both adenosine receptors and adenosine transport.

Fredholm BB, Fastbom J, Kvanta A, Gerwins P, Parkinson F.

Fundam Clin Pharmacol. 1992;6(3):99-111.

PMID:
1628877
47.

Stimulation of the T-cell receptors CD3 and CD2 with OKT3 and OKT11 antibodies activates a common pertussis toxin-insensitive G-protein.

Kvanta A, Gerwins P, van der Ploeg I, Nordstedt C, Jondal M, Fredholm BB.

Eur J Pharmacol. 1990 Dec 15;189(6):363-72.

PMID:
1981560
48.

Characterization of adenosine A1 receptors in intact DDT1 MF-2 smooth muscle cells.

Gerwins P, Nordstedt C, Fredholm BB.

Mol Pharmacol. 1990 Nov;38(5):660-6.

PMID:
2172773
49.

Stimulation of T-cells with OKT3 antibodies increases forskolin binding and cyclic AMP accumulation.

Kvanta A, Gerwins P, Jondal M, Fredholm BB.

Cell Signal. 1990;2(5):461-70.

PMID:
2177619

Supplemental Content

Loading ...
Support Center